Multiplex Antigen Near-Patient Tests in Respiratory Tract Infections

By Staff Writer

November 7, 2023

Understanding Respiratory Tract Infections (RTIs)

RTIs are some of the most common illnesses, causing a significant number of outbreaks annually. Viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) are often the culprits. These RTIs lead to a surge in hospital admissions during winter months, and their symptoms can be very similar, making it challenging to differentiate between them.

Multiplex Antigen Near-Patient Tests

Laboratories typically conduct the gold standard for these tests, reverse transcription polymerase chain reaction (RT-PCR). On the other hand, antigen near-patient tests (NPTs) offer quicker, more affordable, and easier testing. These tests can identify many viruses in multiplex tests or just one virus in singleplex tests, but they are less accurate overall. 

For the purpose of managing and identifying RTIs in primary and residential care settings, multiplex antigen NPTs may be helpful. Their viability and effectiveness are still unknown, though. Although the company states that these tests have acceptable diagnostic accuracy, there are questions regarding the sensitivity of these tests. This applies especially to RSV and influenza. This may reduce their usefulness in contexts involving primary or residential care.

The Current State of Affairs

There is limited guidance available on the use of multiplex antigen NPTs. Two international recommendations were identified, one from the Public Health Laboratory Network and Communicable Diseases Network Australia, which did not recommend the use of these tests. Another evaluation report by the Haute Autorité de Santé (HAS) in France found no clear medical benefit to using these tests in primary care settings. The World Health Organisation ACT-Accelerator Transition Plan has supported the development and acceleration of access to affordable COVID-19 rapid antigen diagnostic tests. This highlights potential interest in these and related technologies.

The Road Ahead

Given the uncertainties surrounding the effectiveness and feasibility of multiplex antigen NPTs in primary and residential care facilities, further studies are required. These studies should prospectively assess the diagnostic performance and clinical utility of multiplex antigen NPTs. The goal is to inform public policy on the use of these tests in these settings. Potentially helping to reduce inappropriate antibiotic use or emergency department visits for non-serious infections.

Reference url

Recent Posts

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

By Staff Writer

August 25, 2025

Bladder cancer treatment has recently advanced, offering new hope for adults with advanced urothelial cancer. If you’re wondering, “What is the most effective first-line bladder cancer treatment for advanced cases in the UK right now?”—the latest update is that the National Institute for Health a...
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...
The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...
EFPIA Response to Tariffs: Concerns Over U.S.-EU Trade Agreement Impact on Pharma Industry

By Staff Writer

August 22, 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed significant concern over the new U.S.-EU Joint Framework Agreement. It is particularly worried about potential tariffs of 15% on pharmaceutical products. The organization argues these tariffs break a three...